Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY · NASDAQ Global Market
-$0.61 today
Vol 0.65M · Avg 0.82M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $158.7M +9.1% | $145.5M +12.9% | $128.9M -29.0% | $181.5M +424.5% | $34.6M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $25.3M +5.1% | $24.1M -1.0% | $24.4M -2.8% | $25.0M +18.8% | $21.1M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 +100.0% | -$29.3M -118.3% | -$13.4M | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $44.9M +5.4% | $42.6M +34.4% | $31.7M +17.8% | $26.9M +67.1% | $16.1M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $91.8M +1354.2% | -$7.3M -120.9% | $35.0M +608.4% | -$6.9M -415.2% | $2.2M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$13.8M -54.7% | -$8.9M +54.2% | -$19.4M +2.5% | -$19.9M -57.1% | -$12.7M | $592.6M | $1.3B | $626.2M |
| Inventory | $1.8M +200.3% | -$1.8M -72.1% | -$1.1M -889.6% | $135.0K +122.2% | -$609.0K | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $3.9M +173.3% | -$5.4M -160.2% | $8.9M | $0 | $0 | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $99.8M +1035.0% | $8.8M -81.1% | $46.6M +261.7% | $12.9M -16.8% | $15.5M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $27.5M -37.9% | $44.2M +244.1% | $12.9M +115.7% | -$82.1M -433.7% | $24.6M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $348.2M +58.4% | $219.8M +0.2% | $219.4M +51.9% | $144.5M +46.6% | $98.6M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$310.0K +73.1% | -$1.2M -269.6% | -$312.0K -81.4% | -$172.0K +42.3% | -$298.0K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 +100.0% | -$33.1M +10.5% | -$37.0M | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$86.2M +18.2% | -$105.3M +17.4% | -$127.5M | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $81.1M -17.7% | $98.5M -16.7% | $118.3M | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$15.0M +43.4% | -$26.5M | $0 +100.0% | -$141.7M -41.7% | -$100.0M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$39.6M +41.2% | -$67.5M -45.3% | -$46.4M +67.3% | -$141.8M -41.4% | -$100.3M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$16.3M -8.3% | -$15.0M -1100.0% | -$1.3M +37.5% | -$2.0M -300.0% | -$500.0K | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $10.2M +57.0% | $6.5M | $0 | $0 | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 +100.0% | -$100.0M | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$3.0M -20.3% | -$2.5M +34.1% | -$3.8M -142.8% | $8.8M +11.6% | $7.9M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$9.0M +17.7% | -$11.0M +89.6% | -$105.6M -1642.9% | $6.8M -7.8% | $7.4M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $299.5M +111.9% | $141.3M +109.7% | $67.4M +611.3% | $9.5M +66.9% | $5.7M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $347.9M +59.1% | $218.7M -0.2% | $219.1M +51.8% | $144.3M +46.9% | $98.3M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Vera Therapeutics, Inc.
NASDAQ:VERA
$2.53B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.20B
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
$2.09B
Nuvation Bio Inc.
NYSE:NUVB
$1.87B
Sionna Therapeutics, Inc.
NASDAQ:SION
$1.69B
AbCellera Biologics Inc.
NASDAQ:ABCL
$1.66B
Immunocore Holdings plc
NASDAQ:IMCR
$1.47B
Biohaven Ltd.
NYSE:BHVN
$1.42B
MannKind Corporation
NASDAQ:MNKD
$1.21B
Janux Therapeutics, Inc.
NASDAQ:JANX
$852.56M
SEC Filings
Recent regulatory filings
No filings found.
Does HRMY generate free cash flow?
Harmony Biosciences Holdings, Inc. (HRMY) generated $347.89M of free cash flow in fiscal 2025.
How much operating cash flow does HRMY produce?
Operating cash flow was $348.20M, before capital expenditures of $310,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.